Skip to main content
. Author manuscript; available in PMC: 2021 Jun 8.
Published in final edited form as: Nanomedicine. 2020 Nov 28;32:102345. doi: 10.1016/j.nano.2020.102345

Figure 5.

Figure 5.

Reduced vismodegib:protein binding with POx-vismo. (A) Tryptophan fluorescence quenching assay by addition of either POx-vismo or conventional vismodegib at given concentration of vismodegib (right); (B) the fraction of unbound vismodegib by addition of either Pox-vismo or conventional vismodegib in diluted FBS solution. (C) Unbound vismodegib after the incubation in FBS; (D) unbound versus protein bound vismodegib in serum 4 h post administration of POx-vismo or conventional vismo. *P < 0.05, **P < 0.005, ***P < 0.0005. Each point is mean ± SEM.